Logo
Whalesbook
HomeNewsCorporate NewsPremiumStocks
HomeNewsCorporate NewsPremiumStocks

GlaxoSmithKline Pharmaceuticals Ltd

₹ 2,348-1.90%
16 Jan 3:43 p.m. – close price
🔗gsk-india.com•BSE: 500660•NSE: GLAXO
Market Cap₹ 39,768 Cr.
Current Price₹ 2,348
High / Low₹ 3,516
Stock P/E42.0
Book Value₹ 101
Dividend Yield1.77 %
ROCE62.6 %
ROE46.4 %
Face Value₹ 10.0
Sales₹ 3,691 Cr.
OPM32.7 %
Mar Cap₹ 39,768 Cr.

ABOUT

GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)

KEY POINTS

Leading Global Health care company[1]GlaxoSmithKline Pharmaceutical is a part of GlaxoSmithKline plc (GSK), a British multinational pharmaceutical company headquartered in London. GSK underwent a merger in 2000 of Glaxo Wellcome and SmithKline Beecham, and is the world’s sixth-largest pharmaceutical company.

Also present in buckets:
Aggressive Growth TriggersExcellent ResultsRevenue GuidanceCapacity Expansion And ProductsRevenue Guidance Vs ActualsCredit Rating UpdatesRed Flags And Poor Performance

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Sun Pharma.Inds.1669.2034.64400497.060.953124.952.5614478.318.9320.2154964.0130.1211543.963117.955.1112.970.07
2.Divi's Lab.6233.9566.60165491.740.47689.0035.102715.0016.1220.4410029.0032.372485.00689.0010.7113.530.01
3.Torrent Pharma.4018.7562.76136012.730.81591.0032.493302.0014.3027.0512248.0032.602166.53600.1716.1213.260.33
4.Cipla1399.4020.77113039.590.941353.373.737589.447.6422.7228349.5725.405441.141351.173.3914.720.01
5.Lupin2174.2023.0799317.100.551484.8373.347047.5124.2321.3024750.6927.254324.631477.925.0812.410.32
6.Dr Reddy's Labs1179.3017.0898427.950.671336.807.288828.309.8322.6934310.0024.645772.201347.102.7412.950.16
7.Mankind Pharma2173.5551.3589725.230.04520.18-22.003697.1620.7715.9813545.6724.121748.55511.515.968.890.55
8.Glaxosmi. Pharma2347.5042.0239768.051.77255.003.15973.63-2.6462.573690.9032.68946.50253.0823.3122.630.02
–Median: 149 Co.390.629.921763.550.1113.4911.71161.7610.5814.89591.7315.9345.2613.963.078.560.22

Quarterly Results

Standalone figures in ₹ crores

Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales
9067997827389538059118111,000946966805974
Expenses
649571615597667587656582681656635554639
Operating Profit
257228167141287218255229319290331251335
Other Income
2212385428-13532363735394434
Profit before tax
26222418717929765269248339306355279351
Tax %
26%27%30%27%27%30%28%27%27%25%27%27%27%
Net Profit
19416413113121645193182249229260205255
EPS in Rs
11.439.687.767.7112.722.6911.4010.7214.6813.4915.3612.0815.05

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Dec 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
2,5463,2882,8262,9032,8723,1293,2252,9203,2183,2163,4073,7233,691
Expenses
2,0242,6602,3492,4822,3612,5222,5662,3232,4622,4172,5072,5532,485
Operating Profit
5226274774215116066585987567999011,1711,206
Other Income
22714712511869106-24781,402104-20146152
Interest
0000016422212
Depreciation
20252527384983796866706766
Profit before tax
7297495765115426643225242,0878358091,2481,290
Net Profit
5024723753373524251103581,691608585919948
EPS in Rs
29.6327.8422.1119.8820.7825.116.5021.1199.7935.8834.5154.2555.98
Dividend Payout %
84%112%113%75%84%80%616%142%90%89%93%100%–

Compounded Sales Growth

10 Years:1%
5 Years:3%
3 Years:5%
TTM:5%

Compounded Profit Growth

10 Years:6%
5 Years:34%
3 Years:-20%
TTM:19%

Stock Price CAGR

10 Years:4%
5 Years:10%
3 Years:22%
1 Year:17%

Return on Equity

10 Years:30%
5 Years:44%
3 Years:36%
Last Year:46%

Balance Sheet

Standalone figures in ₹ crores

Dec 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
8585858585169169169169169169169169
Reserves
1,9321,7672,1201,9441,9951,9731,6711,3282,5081,5841,6151,7801,533
Borrowings
4322110352016191036
Other Liabilities
1,1291,3828649911,8841,7661,2911,5651,9251,5591,7452,1421,897
Total Liabilities
3,1503,2363,0713,0213,9653,9093,1323,0974,6233,3283,5484,1013,635
Fixed Assets
100123204258325432758387331330321284291
Gross Block
299.08319.19228.36305.22408.14561.301,454.59602.89593.89635.93683.12668.95–
Accumulated Depreciation
199.01196.1324.3247.1983.57129.69696.53216.00263.26305.99361.86385.31–
CWIP
621152686059231,003120133020141417
Investments
58485448482524243905438381,1431,338
Other Assets
2,9302,9502,5452,1102,6702,4502,2292,6723,8712,4352,3752,6601,990
Total Assets
3,1503,2363,0713,0213,9653,9093,1323,0974,6233,3283,5484,1013,635

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Dec 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
2673411382324754114915958204885791,280
Cash from Investing Activity
198178499303-107-154-63408-42080515-37
Cash from Financing Activity
-490-497-638-511-307-358-428-696-524-1,544-562-769
Net Cash Flow
-2522-12561-1020307-124-25132474

Ratios

Standalone Figures in ₹ Crores / Yearly

Dec 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
141116211914112723222429
Inventory Days
10889155111147131135153144128146124
Days Payable
8874967214810999131156122174188
Cash Conversion Cycle
34267561183747491127-4-36
Working Capital Days
-46-49256-91-72-35-38-96-59-66-102
ROCE %
35%41%28%22%26%31%33%37%36%36%51%63%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters
75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%
FIIs
2.28%2.28%2.41%2.50%2.93%3.48%4.02%4.36%4.50%4.52%4.89%4.79%4.63%
DIIs
10.29%10.31%10.25%10.01%8.64%7.90%7.51%7.34%7.30%7.79%7.71%7.75%7.70%
Public
12.43%12.43%12.35%12.48%13.42%13.62%13.48%13.30%13.21%12.69%12.41%12.45%12.67%

* The classifications might have changed from Sep'2022 onwards.ℹ️

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

GlaxoSmithKline Pharmaceuticals Submits SEBI Compliance Certificate for Q4 FY26

9th April 2026, 4:13 pm

GSK Pharma Shareholders Endorse Appointments of Mr. Ronojit Biswas Via Postal Ballot

9th April 2026, 4:55 am

GlaxoSmithKline shareholders approve appointment of Mr. Ronojit Biswas as Director and CFO via postal ballot

9th April 2026, 4:54 am

GSK Pharma Receives ₹2.01 Cr Tax Demand Order, Plans Appeal

31st March 2026, 10:22 pm

GSK Pharmaceuticals Announces Trading Window Closure from April 1, 2026

25th March 2026, 8:33 pm

Published by Other Websites

External media mentions & references

RIL $3B Deal, Tata Motors Price Hike, Sun Pharma FDA Nod: Stocks in Focus

17th March 2026, 7:35 am

Pharma Talent Shift: GSK Legal Chief Joins MSD India

9th March 2026, 4:55 pm

GSK India Pushes Shingles Vaccine Amid Rising Chronic Disease Burden

26th February 2026, 9:25 pm

Alembic Pharma Secures USFDA Approval for Seizure Drug, Eyes $27M Market

26th February 2026, 3:38 pm

Indian Stocks Eye Higher Open; NHPC Tender, BSE Profit, JLR Plant Drive Action

10th February 2026, 6:50 am

News Articles

Editorial & research coverage

GSK Pharma Net Profit Soars 29% on Robust Revenue, Margin Expansion
GSK Pharma Net Profit Soars 29% on Robust Revenue, Margin Expansion

9th February 2026, 6:14 pm

India Budget 2026: Drug Duty Cuts Offer Targeted Relief
India Budget 2026: Drug Duty Cuts Offer Targeted Relief

3rd February 2026, 11:08 am

Pollution Spurs Record Respiratory Drug Sales: ₹1,950 Cr Surge
Pollution Spurs Record Respiratory Drug Sales: ₹1,950 Cr Surge

12th January 2026, 5:19 am

₹200 Becomes ₹1.8 Lakh! Forgotten Share Certificate Unearths Huge Wealth - Is Your Old Paper a Goldmine?
₹200 Becomes ₹1.8 Lakh! Forgotten Share Certificate Unearths Huge Wealth - Is Your Old Paper a Goldmine?

15th December 2025, 6:26 pm

India Pharma Surges 8.6%! But What's Behind The Growth & Which Stocks Are Winning (And Losing)?
India Pharma Surges 8.6%! But What's Behind The Growth & Which Stocks Are Winning (And Losing)?

15th December 2025, 5:27 pm

Documents

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Board Meeting Intimation for Un-Audited Financial Results For The Third Quarter & Nine Months Ended 31St December 2025.

6 Jan - Board meeting on 9 Feb 2026 to approve Q3 & 9M unaudited results (31 Dec 2025).

Disclosure Under Regulation 30

1 Jan - Maharashtra GST order dated 31-Dec-2025 demanding Rs.35,07,895 for FY2021-22 (tax, interest, penalty).

Volume Movement Letter

31 Dec - Dec 31, 2025: Clarifies volume spike is market-driven; no undisclosed price-sensitive information.

Disclosure Under Regulation 30

31 Dec - Karnataka GST order (30-Dec-2025) demands Rs.8,56,90,938 for FY2021-22 (tax, interest, penalty).

Annual Reports

Financial Year 2025

(from bse)

Financial Year 2024

(from bse)

Financial Year 2023

(from bse)

Financial Year 2022

(from bse)

Financial Year 2021

(from bse)

Financial Year 2020

(from bse)

Financial Year 2019

(from bse)

Financial Year 2018

(from bse)

Financial Year 2017

(from bse)

Financial Year 2016

(from bse)

Financial Year 2015

(from bse)

Financial Year 2014

(from bse)

Financial Year 2013

(from nse)

Financial Year 2013

(from bse)

Financial Year 2012

(from nse)

Credit Ratings

No credit ratings.

Concalls

Nov 2025

PPT

Aug 2025

TranscriptPPT

May 2025

TranscriptPPT

May 2025

PPT

Feb 2025

TranscriptPPT

Oct 2024

Transcript

Aug 2024

Transcript

May 2024

Transcript

Feb 2024

TranscriptPPT

Mar 2023

Transcript

Aug 2022

TranscriptPPT

Aug 2021

PPT

Feb 2020

PPT

Stock Analysis

Description

  1. GlaxoSmithKline Pharmaceuticals researches, manufactures, and distributes a range of medicines and vaccines.

Key Growth Triggers

  1. Strategic investments in key portfolios.
  2. Preparation for significant oncology product launches.
  3. Expansion of the vaccine business and focus on new growth platforms.

Order Book

Currently no data available for Order Book.

Key Red Flags

  1. Outstanding GST demand orders from Maharashtra and Karnataka authorities for FY21-22.
  2. Evaluation of a substantial court decree from May 2025.

Key Dates To Watch

  1. Board meeting scheduled for February 9, 2026, to approve Q3 FY26 financial results.

Corporate Announcements

9th Apr 26
Impact Rating: 3
GlaxoSmithKline Pharmaceuticals has submitted its SEBI compliance certificate for the quarter ended March 31, 2026, to the exchanges, confirming proper handling of share dematerialisation processes by its registrar.
8th Apr 26
Impact Rating: 7
GlaxoSmithKline shareholders have overwhelmingly approved the appointment of Mr. Ronojit Biswas as a Director and as Whole-time Director & Chief Financial Officer (CFO). Both ordinary resolutions received significant support, with over 99% of votes cast in favour.
8th Apr 26
Impact Rating: 4
GSK Pharma shareholders strongly supported the appointment of Mr. Ronojit Biswas as Director and as Whole-time Director & CFO in a postal ballot. Over 99% of votes favoured both resolutions, conducted via e-voting ending April 8, 2026.
31st Mar 26
Impact Rating: 4
GlaxoSmithKline Pharmaceuticals announced a ₹2.01 crore tax demand order for AY 2020-2021, including ₹1.11 crore TDS and ₹0.90 crore interest, which it plans to contest.
25th Mar 26
Impact Rating: 6
GlaxoSmithKline Pharmaceuticals Limited is closing its trading window from April 1, 2026, until 48 hours after the declaration of audited financial results for the fourth quarter and fiscal year ended March 31, 2026. The board meeting date is yet to be announced.